Vaxart, Inc. (VXRT) Earnings Call Transcript & Summary
August 8, 2022
Earnings Call Speaker Segments
Brant Biehn
executiveGood afternoon, and thanks for joining us on today's call. On the line from Vaxart we have Andrei Floroiu, our Chief Executive Officer; Dr. Sean Tucker, our Founder and Chief Scientific Officer; and Dr. James Cummings, our Chief Medical Officer. Before we begin, please note that on this conference call, Vaxart may issue forward-looking statements, which include statements regarding the company's financial results, financial guidance, its future business strategies and operations, and its product development and regulatory progress, including statements about its ongoing or planned clinical trials. A number of important factors could cause actual results to differ materially from those discussed in these forward-looking statements, including uncertainty inherent in the clinical development and regulatory process, the extent and duration of the impact of the COVID-19 pandemic, and other risks described in the Risk Factors section of Vaxart's most recently filed annual report on Form 10-K and other periodic reports filed with the SEC. Except as required by law, Vaxart undertakes no obligation to update any forward-looking statements after this call. I'll now hand the call over to Andrei Floroiu. Andrei?
Cezar Floroiu
executiveThanks, Brant. I appreciate everyone joining us. During our June 22 call, we discussed how Vaxart is dedicated to keeping investors updated on a more frequent basis. We welcome this opportunity to review what we've accomplished lately and to share what's coming next. This is actually the company's first quarterly call in a very long time, and the moment feels ideal. Vaxart's goal is to realize the complete promise of our oral pill vaccine platform, which we think has the power to change not only vaccines but also how we approach — how we carry out vaccination across the globe. At Vaxart, we picture a future where vaccines you swallow as tablets are available, so that getting immunized becomes simpler, pain-free, and faster for many more individuals, requiring only a cup of water. In that future, tablet vaccines taken by mouth provide stronger safeguards because they engage mucosal defenses. While orally administered vaccines could yield huge advantages throughout all intended uses, they may offer particularly significant gains compared with noro vaccines when pandemics strike. We actually think our swallowable tablet vaccines have the power to reshape the way we fight the ongoing COVID-19 pandemic as well as future ones. Recognizing this vast potential is what drives everyone here at Vaxart. Equally significant, that identical outlook and promise has generated extraordinary excitement among the people who own stock in our company, and we extend our gratitude to them for turning Vaxart into something distinctive by confirming the mission we pursue. It's a genuine pleasure to be here with all of you today. During the investor webcast we held in June 2022, I stated that in my view Vaxart currently finds itself in the most advantageous situation it has ever held across its entire 15-year history, after a sweeping overhaul spanning the previous 2 years that enabled us to bring essential competencies in-house and reinforce our workforce, extending from the laboratories to the GMP suites and up through the leadership group. So what this boils down to is that Vaxart is in a stronger spot than it has ever been to take advantage of what our oral vaccine platform can do, by moving several programs forward simultaneously. And the timing works in our favor, because the demand for improved next-generation vaccines has never been clearer. COVID-19 as a whole, and the Omicron variants in particular, have exposed just how many serious weaknesses noro vaccines have. On top of that, Monkeypox is a reminder that COVID-19 probably won't be the final event of this kind that we witness during our lives. The benefits oral pill vaccines might deliver are considerable, especially when pandemics hit. Oral pill vaccines will mean more people actually get vaccinated. An oral tablet for widespread immunization might be administered at a far quicker pace compared to injections. Also, the possible benefits of our vaccines extend far past just the oral pill approach, which my colleagues Dr. Tucker and Cummings will explain in greater depth. By triggering mucosal immunity, our vaccines may be able to deliver broader defense against a wider spectrum of variants and pathogens, keep you protected for an extended period, and reduce transmission. I'd now like to walk you through two primary clinical initiatives: COVID-19 and norovirus. One challenge when developing a COVID-19 vaccine is that the virus continually changes — basically, it's a shifting target. Our COVID-19 vaccine program started when only a single strain existed. As more variants showed up, we grew increasingly confident that our oral tablet candidate could offer superior protection. That confidence stems from mucosal immunity's cross-reactivity plus robust T cell responses. To fully exploit this distinctive cross-reactivity, we believe the best path involves solutions built to last, expanding what we're working on to cover constructs targeting the new Omicron variant of concern, day 4 and 5, and looking at them both as monovalent and bivalent constructs. Several clinical and strategic advantages could come from this. It also strengthens our position for the human Omicron challenge study in the U.K. — I'll remind you this is the first study of its kind announced anywhere in the world. It places us in a stronger position versus our needle-based rivals, since everyone only recently began working on BA.4/5 variants. And it aligns with what regulators like the FDA recommend and expect, given they recently amended boosters for the targeted BA.4/5 variant. So we're quite enthusiastic about what our enhanced portfolio could achieve, and my colleagues will explain in greater depth its future-proof potential. Let me now move to our other lead clinical program. Over this quarter, we've kept making headway with our norovirus program, adding to the clinical evidence that makes us increasingly enthusiastic about what this program could achieve. The latest data from our trial involving elderly adults is highly encouraging, since it indicates activity comparable to what's seen in younger adults; that's frequently not true of injectable vaccines, so it gives yet another possible differentiator for our oral fill vaccine candidate and boosts our confidence as development proceeds. I'll now pass the call to Dr. Sean Tucker, who will go over the many advantages our oral vaccine technology provides. Sean?
Sean Tucker
executiveThank you, Andrei. To begin, I want to point out to everyone listening that we've previously shared results from several data sets that make it plainly evident our approach can produce a strong mucosal IgA response. Such responses might deliver better protection at the specific anatomical locations — the places where infections truly enter the body, like the respiratory tract and the intestinal system; this kind of advantage isn't genuinely seen with shots, which lean toward generating a blood-based serum response. At this point, evidence keeps accumulating that backs our conviction that mucosal vaccines are capable of delivering solid protection against many kinds of infectious disease; once more, this evidence reinforces what other groups may achieve in lowering the chance of infection and transmission and, as a result, tackling major public health difficulties. So, as Andrei mentioned earlier, the COVID pandemic exposed problems tied to large-scale immunization drives relying on injected vaccines. Once again, a number of these demand not merely cold but ultra-cold chain handling. Such difficulties have unquestionably restricted the rollout of potentially life-saving vaccines to low-income nations and rural regions, even inside middle- and high-income nations; they additionally call for trained staff and specialized equipment, both of which have been in short supply, particularly throughout the pandemic. Shots also mean people must journey to a vaccination location, which further raises potential — raises obstacles to vaccine access. By contrast, our vaccines stay stable at room temperature and come in an oral format. That dramatically streamlines mass immunization efforts by allowing possible self-administration at home with no need for any special equipment or trained staff, while also removing the requirement to book and travel for an appointment. Another aspect of our technology is that it truly cuts down a great deal of medical waste, something that has been an environmental and economic burden across the COVID-19 pandemic. Lastly, what I'd like to bring up is that vaccines only help when patients actually receive the vaccine, and our oral vaccine might get past some vaccine hesitancy among individuals who dislike injections and, as a result, possibly raise the number of the people — the number of people who can be protected against injection. Across the past several months, we've shared numerous data sets backing the wide potential of our COVID-19 vaccine candidate to address the challenges posed by the evolving virus, and that continues to — and the virus that keeps overcoming immune protection offered by the currently approved vaccines. Very recently, we published data from a preclinical hamster study conducted by — with researchers at Duke University; once again, this appeared in Science Translational Medicine. I believe it showed that our S-only COVID-19 vaccine candidate was able to reduce disease and airborne transmission. We've likewise shown preclinical data demonstrating that 2 of our vaccine candidates aimed at the SARS-CoV-2 S protein for Wuhan or the S protein for Omicron could protect hamsters when challenged with the Omicron-BA.1 variant. Also, we've secured the preclinical findings that show giving the S-only or the S+N COVID-19 vaccine candidate to non-human primates via the mucosa led to meaningful rises in serum IgG, along with IgA, plus as much as a 1,000-fold boost in nasal IgA responses targeting SARS-CoV-2. What's more, when every vaccinated animal was challenged with the beta strain of SARS-CoV-2, one of the newer variants, there was a notable drop in viral titers within the nasal passages relative to the unvaccinated control; and once again, that holds true even though the vaccines were created against different viral strains, like Wuhan. Beyond the expanding set of strong data showing our vaccine candidates' efficacy and safety, we're making key moves to accelerate clinical development. It's clear that we, along with others, see enormous potential in mucosal vaccine technology, and we're dedicated to transforming that potential into vaccines capable of tackling major public health issues and generating value for our investors. At this point I'll hand the call to James Cummings, who will go over recent improvements, the next steps, and upcoming milestones for our COVID and norovirus vaccine candidate. James?
James Cummings
executiveThank you, Sean. I'd like to start by discussing the clinical vaccine program we have for COVID-19. Fresh results from the Phase I study of our S+N candidate indicated that this candidate triggers SARS-COV-2 specific IgA antibodies within saliva as well as nasal samples taken from the human subjects, and it demonstrated cross-reactivity against numerous coronaviruses that are even more divergent, including the circulating variants of SARS-CoV-2 that we observe at present; we feel this wide cross-reactivity serves as a significant differentiator for Vaxart, particularly given how novel virus strains that evade immunity from the currently approved needle-based vaccines keep evolving. Last month, we shared that we've entered into an agreement with hVIVO Services, which is a subsidiary of Open Orphan. Through this arrangement, hVIVO is going to carry out a characterization study and successfully develop a human challenge model rooted in the Omicron variant of SARS-COV-2, with the goal of running a subsequent Phase II human challenge trial for our COVID-19 vaccine pill candidate; regarding what comes next, we have a number of truly key near-term milestones within our COVID-19 vaccine development program. To start, we remain on track to report preliminary data from Part 1 of the Phase II COVID-19 clinical study during the third quarter of this year. Next, we plan to decide whether to move either our S only or our S+N candidate forward into a Phase II/III trial during H1 of 2023. As a company grounded in science and driven by data, we are dedicated to tracking the emerging science as new viral variants keep evolving. When choosing a candidate to move into the next clinical stage of development, we'll take into account the results once we receive them from the ongoing Phase II trial of our S only candidate along with the longevity data from the S+N candidate; furthermore, as Andrei mentioned, in light of recent FDA guidance, we are assessing both Wuhan and Omicron-based vaccine candidates to figure out the truly optimal approach for delivering maximum protection against strains circulating right now as well as strains likely to emerge later on. Everyone at Vaxart is determined to have a candidate with a strong likelihood of success once we enter Phase III and the potential to deliver benefit to people across the globe and to our investors. We're also continuing our work with the Indian government to launch a Phase Ib trial in India. As we talked about last month during our call, we've reached out to the regulatory authorities in India concerning our COVID-19 study as both a boost for those who have been previously immunized as well as a primary vaccination in a vaccine-naive population if possible, and it's been received very well; that being said, the Indian regulatory pathway does take time. Additionally, since our vaccine and our platform are novel relative to the injected needle-based vaccines that are available, testing of our product by the Indian regulatory authorities does require some enhanced capabilities on their end to evaluate our vaccine candidate, and we have been very responsive to their questions. We are eager to begin our trial in India as soon as the regulatory assessment wraps up; our plan is to fine-tune that trial using information from Part 1 of our Phase II COVID-19 study that was run in the United States. Let me now shift to what we've recently achieved and what comes next with our norovirus program. During June, we shared encouraging initial results from a Phase Ib study of our norovirus vaccine candidate involving participants between 55 and 80 years of age, and those results revealed that every dose triggered quite strong immune reactions, along with IgA antibody screen cell generation that depended on the dose. Importantly, these outcomes matched what earlier research in number populations had found. And this matters — normally that isn't what happens, since immunity tends to decline as people get older, and seniors usually respond less strongly to vaccination compared with younger individuals. These findings have us quite enthusiastic, as they showcase the strength of our vaccine technology and our platform; plus, adults beyond 55 years of age face greater risk from norovirus infection, with 7.5% of that group getting infected each year. What we've seen so far indicates that our norovirus vaccine could potentially deliver protection against norovirus over a broad range of ages. Leveraging the encouraging data our norovirus program has produced thus far, we plan to launch a Phase II trial of a bivalent norovirus vaccine before this year ends; this vaccine would contain 2 norovirus proteins, G1.1 and G2.4. Those are the ones that are — the virus trains are typically behind the majority of norovirus worldwide, and they might spark even stronger immune reactions than what our monovalent candidate produced; we anticipate sharing initial results from the Phase II norovirus challenge study that's underway around the end of the first quarter of 2023 or the start of Q2. Before handing things back to Andrei, I want to express how proud I feel about what our team has achieved, particularly given the difficulties that we and so many others have encountered while working through a continuing global pandemic and global supply chain difficulties. I want to thank each person at Vaxart, our academic and clinical collaborators, and our volunteers taking part in our clinical studies for helping us move closer to our vision of transforming the vaccine landscape. I also want to thank our investors. You've placed your confidence in us, and we will deliver. Over to you again, Andrei.
Cezar Floroiu
executiveThank you, James. Prior to starting the Q&A portion, I'd like to offer a brief comment regarding our cash situation and the milestones ahead. As of June 30, 2022, we hold a robust financial position, with $131 million in cash and cash equivalents. That gives us runway extending into the second half of next year, 2023. Let me now walk through the key milestones we anticipate across roughly the coming 12 months. We expect top line data from the Phase IIa COVID-19 clinical study during the third quarter of this year, 2022. We anticipate selecting the COVID-19 vaccine construct in Q4 of this year, with clinical trials kicking off in the first half of next year. Next comes updating the plans for our India trials once we've determined which COVID-19 vaccine candidate to advance. Following that, we expect the Phase II trial of Vaxart's bivalent norovirus vaccine candidate to begin in Q4 of this year. Then we anticipate top line data from our ongoing Phase II norovirus study toward the close of the first quarter or in the early part of the second quarter of 2023. And lastly, the Omicron human challenge trial in the U.K., utilizing the selected COVID-19 vaccine construct, should get underway in the second half of 2023. So we have a great deal of significant progress coming over the next year to 1.5 years, including a major value inflection point. We're therefore quite enthusiastic about continuing to work diligently toward realizing the complete potential and worth of our distinctive oral pill vaccine platform. I'd like to express gratitude to all of you who have joined our call today, and particularly to our investors for their ongoing backing of our mission; we'll now move into the Q&A portion of the call. Alex?
Pete Stavropoulos
analystPete Stavropoulos speaking on behalf of Charles here. Andrei, along with the rest of the team, congratulations on everything you've pushed forward. A few things I'd like to ask. The first is about change. When it comes to securing approval of a vaccine as a COVID booster, what requirements do you expect agencies like the FDA and the EMA to set when that vaccine hasn't been authorized, or hasn't produced efficacy data from a bigger trial, in the role of a primary shot — have those agencies given any guidance? And related to that, have conversations happened with regulators regarding data from the challenge study that could back a potential booster filing, particularly if clear links can be drawn between IgA responses and protection?
James Cummings
executiveJames Cummings here — thank you. So on that, roughly two points. First, we've maintained very close and ongoing communication with regulators — here in the United States with our own FDA, and abroad with the EMA, MHRA, and agencies in additional nations around the world. As far as the route ahead goes, it truly hinges on the data we have available. That's exactly why our challenge study matters so much — examining a challenge study and obtaining, I'd say, the crucial answer regarding protection from infection. Pairing that with an immunogenicity marker, allowing us to establish a correlate of protection, matters greatly, and beyond that, examining how much nasal shedding of virus drops — virus shedding that reduces transmission. Those two or three items, plus a reduction in symptomatic disease, will, I believe, significantly help shape what a follow-on Phase 3 study ought to look like, while also giving regulators enough to offer us a clearer sense of the path ahead; it further hinges on where the pandemic stands at that moment. We know SARS-CoV-2, the virus responsible for COVID-19, carries a very sloppy gene editor, meaning additional strain variation will keep appearing; given that, should the global picture involve more disease, more death, more quarantine problems, then I believe the stakes rise for delivering additional solutions — more next-generation options — out there both faster and farther.
Pete Stavropoulos
analystGreat. I have one thing about the norovirus program — from what I understand, you intend to start a Phase II trial for the bivalent vaccine candidate during 4Q. Could you give some sense of how large that study will be and how long it will run? Also, are you going to assess immunogenicity alone, or both immunogenicity and efficacy, and in what ways would this trial be different from prior norovirus studies this company has run? And do you believe the results from this, together with the challenge study, could support a registrational study?
James Cummings
executiveThat's a terrific question. Regarding how that subsequent study is designed, it's going to be a Phase II rather than a Phase III, yet immune correlates will be examined in it as well; we'll draw on certain data that are coming out of our challenge study; and we'll also be evaluating preliminary efficacy. Some of those data will be gathered by us. My sense is that all of this is going to be useful for informing — once our challenge study concludes, it will be useful for informing what we do next regarding a bigger, sturdier study. So we're examining dose confirmation using the buy-down approach, examining the findings from that challenge study, which once more is going to fall in late Q1, early Q2 of next year, and bringing that amalgam together to the regulatory bodies for additional discussion.
Pete Stavropoulos
analystOkay, and if I could squeeze in one final question, if that's all right. Regarding the norovirus vaccine, where do you see it slotting into the immunization schedule, let's say in the U.S.? And who do you believe would gain the most from such a vaccine?
James Cummings
executiveSo, where does it fit in the schedule, and who benefits most? Well, norovirus impacts everyone, correct? But it hits us hardest at the beginning of our lives and toward the end. Kids through age 5 get sick with this quite often. Then, once we get past age 55 or 62, we observe another rise in symptomatic cases. And the expense, for those listening who might not have seen the Johns Hopkins report, the yearly cost in the United States from norovirus infection, within the U.S. by itself, throughout the population exceeds 10 billion, with 1 billion of that. So looking at that, it's the elderly and the young who bear the brunt, yet there are additional groups too—healthcare providers, restaurant workers, those in hospitality, people serving in the military; all of them could gain from a norovirus vaccine. So I see this as a very broad distribution when it comes to vaccination strategy.
Kumaraguru Raja
analystCongrats as well on everything you've achieved. Now, concerning the Phase II results, some published reports indicate that a prior Omicron infection confers protection too. So how do you view the capacity of the Wuhan S-only to deliver protection once more against BA.4 and 5? Perhaps that's a good place to begin.
James Cummings
executiveSean, would you like to kick things off, and then I'll wrap up.
Sean Tucker
executiveAbsolutely, I agree — that seems like the ideal path forward. And yes, as you mentioned, there's data suggesting that prior infection with Omicron gives a degree of protection when it comes to later infections. How long that protection persists is unknown; it might not endure indefinitely. It's been observed that titers decline both from natural immunity and from the injected vaccine. Going forward, one question we're interested in is whether our booster — whether that involves Wuhan — provides protection against other things that emerge; we've observed a lot of cross-reactivity when we examine, particularly, T cells and the nasal mucosa; so we believe our approach is more likely to be cross-reactive. James could probably speak to more of the trial-related issues. From where we stand, though, we think there's solid evidence that we can be cross-reactive. There's also the possibility we can do better by using an Omicron BA.4/5, and we intend to assess that in the clinic to determine the best way forward.
James Cummings
executiveAppreciate that, Sean. So with that in mind, our plan is to obtain those data — which, as we noted, are now in hand this quarter for Part 1, or Phase II — and beyond that, examine how other strains factor in. The FDA's guidance calls for us to include BA.4 and BA.5. Having the Omicron strain is something we want. We want those data available, and we want to take a data-driven approach in deciding what we advance into the challenge model and into larger studies. So expect further updates once the data arrive.
Kumaraguru Raja
analystAll right. Moving on to the vaccine supply. What quantity of the Wuhan do you currently have? And how fast can you scale up production of the new constructs?
Sean Tucker
executiveThis is Sean. From a supply perspective, I believe we're well positioned to move forward with the next Phase II study, if I'm not mistaken. Second, since we now handle our manufacturing in-house, we have 2 separate manufacturing "facilities" at Vaxart and in Northern California, and I believe we can now move very quickly to produce supplies for new constructs; so James, would you like to add anything?
James Cummings
executiveAbsolutely, Sean — I share that view. At this point, I'd say we've reached an ideal position when it comes to steering where we want production to go. As you pointed out, we've got both available capacity and finished goods left over from that prior S-only construct, and I'm eager to see upcoming studies that go further.
Kumaraguru Raja
analystAll right, and regarding the norovirus bivalent, do you also have sufficient trucks to proceed with the Phase II trial as planned?
James Cummings
executiveBased on how things are scheduled, yes, we're producing those products right now. And once more, with a bivalent strategy, examining both G1.1 and G2.4. We've administered them to people previously; this time it will be a bigger study, a dose confirmation study that looks at that outcome too.
Brant Biehn
executiveThanks, Alex. We received a handful of questions in writing while the call was going on. One concerns the India study. James, I believe you already addressed that during your opening remarks, so we won't spend time on it. The following one, James, is a clinical question regarding norovirus. It may be asking when commercialization of the norovirus product could happen. My guess is that it's likely about the shape of the clinical development plan. Would you like to speak to that briefly?
James Cummings
executiveOkay. So like I said, at this point, with regard to the norovirus program, a Phase II challenge study is underway right now. Data from that ought to arrive near the close of Q1 or in the early part of Q2 next year. In addition, we're starting a Phase II dose confirmation for the bivalent norovirus vaccine in candidates as we move ahead. So my view is that you need results from both of those trials before having a follow-up conversation with the FDA and considering a potentially large Phase III. Large is a relative word, of course. With correlates of immunity, I suspect we could likely proceed using a more sensible figure. Thus a Phase III might involve observed efficacy, and it might also rest on immunogenicity; the information from the studies coming up, I believe, will truly help shape that process. Then following the Phase III study, I think that with solid data available and volume secured, it's simply a matter of moving into commercialization. Brant, would you like to say anything about that?
Brant Biehn
executiveI'm sorry, James, I didn't catch that last thing. What did you ask?
James Cummings
executiveWhen it comes to commercialization, would you like to say anything about that part, or touch on it?
Brant Biehn
executiveSure, I can do that quickly. I think one of the most important items from a commercial standpoint was getting the Health Economics piece published, since that is really helpful in conversations with governments, both regarding their willingness to accept the vaccine and then to pay for it. And I think what we demonstrated in the health economic study that was conducted is that norovirus disease right now each year in the U.S. has roughly 10x the impact that rotavirus had. And we all know there is an effective rotavirus vaccine available on the market that is well covered and widely used in this country. So from a commercial standpoint, I think we believe it looks good in that phase. And then coming back to one of your earlier questions that you had answered regarding that being the under age 5 population versus the over 65 population, we believe this probably would be used like the influenza vaccines currently used in the U.S.
James Cummings
executiveThanks for that.
Brant Biehn
executiveLet me check a few more items that came in here. Actually, I believe a pair of the questions we received were about the White House COVID Summit that took place last month. James, I'll send this one your way to start. So following that summit in late July, what stood out as the main outcomes and lessons?
James Cummings
executiveThank you. So everyone there basically agreed that to make it past this pandemic, we're going to need Gen 2 vaccines — particularly given how the virus mutates and how variants shift. The first generation of vaccines was an excellent initial move, yet it left the door open for the virus. People recognized how much mucosal immunity matters. And we view our vaccine as a possible answer to those issues. At the meeting, Dr. Akiko Iwasaki was present, and she responded to a question Francis Collins asked, and I'll quote her briefly. An approach like an oral pill vaccine from Vaxart that brings about mucosal immunity is, in my view, extremely promising. The thing is, a great deal of virus leaves the oral cavity. So if your real goal is stopping transmission, you must have a defense system in the oral cavity and in the nasal cavity too; so I believe it has a great deal of promise. I'm aware the Phase I trial is producing encouraging data on durable responses. I believe we need several distinct approaches attempted, since we're not going to wager on one single thing succeeding when it comes to transmission-blocking vaccines. The more we can test, the better, though I think we need the resources and the assistance to reach that point. And once more, that's — those are my words — those are Akiko's words from that meeting; so I think, once more, there's an understanding that what we're doing is picking up momentum, and I look forward to additional results ahead.
Brant Biehn
executiveThanks, James. The following question is really for Sean, I believe — it's probably somewhat more on the preclinical side. So here's the question: in what ways would the oral tablet vaccine from Vaxart stand apart from the intranasal vaccine candidate? Sean?
Sean Tucker
executiveYeah, that's a great question, honestly. Something we strongly believe is that, at least from what we've seen preclinically, both the intranasal route and the oral route are capable of performing quite effectively when it comes to generating new responses. Our view is that tablets taken by mouth are simply far simpler to give to people. Beyond that, there have been some genuine difficulties around creating intranasal vaccines; take FluMist, for instance — it's the sole intranasal vaccine that's been approved. We're aware it performs considerably better in younger children who lack much immunity to flu, since flu appears to interfere with its use. Another point is that certain intranasal vaccines have produced fairly serious side effects — the nasal flu vaccine from Berna Biotech, for instance, wound up triggering Bell's palsy and got withdrawn from the market; and once more, given how close the brain is when you administer something into the nose, problems are possible. Both of those could perhaps be surmounted, yet we continue to believe that looking ahead, an oral vaccine is simply easier for the person receiving it and might deliver the same kind of community benefit that comes with intranasal administration.
Brant Biehn
executiveGreat. Here's another one, and it may wind up being wider-ranging when it comes to what all 3 of you might say, since the question itself is broad. Where do things stand right now with the human papillomavirus vaccine? And how big is the market opportunity? James? I believe we ought to begin with you on this, then hand it off.
James Cummings
executiveAbsolutely. The question of a preventive vaccine or a therapeutic one comes up often. In the U.S. there is a preventive vaccine available, for children aged 12 or 15 and up, and you can get it worldwide. The unfortunate side of things is that fewer than 60% of American boys and girls have completed vaccination; and in most nations, that figure is surely lower. HPV-related cancer typically appears between age 50 and 65, which varies by the specific cancer type. So sadly, 30,000-plus HPV cancers still occur annually in the U.S. That represents a great deal of illness that will persist well into the foreseeable future, particularly if we manage to strengthen our preventive vaccination approach here in America. Following up on these cancers is costly. Treating them is difficult; and our belief is that a lot of people would prefer an oral tablet vaccine over some of the therapies currently used for the cancer or pre-cancerous lesions we encounter today. Andrei?
Cezar Floroiu
executiveYes, thanks James. As James mentioned, sadly a significant market remains for an HPV vaccine, in the U.S. and outside it as well. What's intriguing though about our HPV program from a strategic standpoint is that it would be our first therapeutic vaccine, and it might also create a new category for us, so this would represent a quite compelling broadening of where our platform can be applied. And as a lot of you are aware, T cells play a very significant role in cancer. So this could tap into yet another aspect of our platform, something especially underscored by the Phase I COVID-19 data we obtained. Sean, perhaps you'd like to weigh in or elaborate on that a bit?
Sean Tucker
executiveAlright, yes. A number of years back, we developed vaccines targeting HPV16 and 18, and ran preclinical testing on them. We understood these could basically stop tumors from growing, or shrink them, in mice. We considered that a pretty great outcome. We also know they were capable of generating quite potent T cell responses against the vaccine candidates. Then, several years ago, a paper came out from Connie Trimble — I believe this was during her time at Cornell — and it proposed that generating a CD8 T cell response, that cytotoxic T cell response, alongside mucosal homing markers, was the single most critical factor when it came to clearing lesions and cervical dysplasia. And so, we know our platform — and definitely in the COVID space — demonstrated that we could produce those kinds of responses. Therefore, we're genuinely optimistic that if our platform is used to generate responses against HPV, we might end up with a really effective therapeutic vaccine for this indication. So yes, we're extremely enthusiastic about it.
Brant Biehn
executiveGreat. The final question really relates to partnerships, and we've received a few questions that are somewhat alike in how they're posed, but I'll attempt to combine them. Andrei, I believe this one is headed your way. How do you think about possible partnerships for the COVID-19 programs or the norovirus programs? And would a partnership help move the program forward? So, Andrei?
Cezar Floroiu
executiveAnd Brant, the last part of the question, please?
Brant Biehn
executiveAnd would that partnership speed the program along? Would it accelerate the program?
Cezar Floroiu
executiveAll right, I get it. So here's the thing — when it comes to partnerships, we're never closed off to talking, since our goal is genuinely to examine every avenue for boosting shareholder value and speeding up how quickly our platform reaches its full potential. That's why we've got several programs going. We've had talks and remain willing to talk with a range of parties, and we keep being open to looking into those possibilities both inside the U.S. and outside it, for COVID-19 as well as norovirus. With that said, Vaxart can now choose the right timing for when we'd like to bring in a partner, and also what kind of partnership we might wind up forming. So at this point we aren't giving out many specifics. Once it makes sense, we will, but for a development-stage biotech company such as ours, partnerships remain a key and compelling instrument; so once more, that possibility is something we welcome. As for accelerating the program, well, it truly hinges on several things. It hinges on what sort of partnership it is, hinges on which program, and clearly an investor partnership matters because both sides gain and the asset's worth goes up. So one possible upside of teaming up is that the program moves faster.
Brant Biehn
executiveGreat. Thanks, Andrei. So that wraps up the question-and-answer section of today's call. We appreciate everyone joining us.
Cezar Floroiu
executiveThank you.
Operator
operatorThanks a lot. That wraps up the call for today, so feel free to hang up whenever you're ready. We appreciate you joining us, and enjoy the rest of your day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Vaxart, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Vaxart, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Vaxart, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.